Form 8-K - Current report:
SEC Accession No. 0001654954-21-011105
Filing Date
2021-10-15
Accepted
2021-10-14 21:32:54
Documents
16
Period of Report
2021-10-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8K vtgn_8k.htm   iXBRL 8-K 21061
2 PRESS RELEASE ISSUED BY VISTAGEN THERAPEUTICS, INC., DATED OCTOBER 14, 2021 vtgn_ex991.htm EX-99.1 15946
3 IMAGE vtgn_ex991img1.jpg GRAPHIC 4680
  Complete submission text file 0001654954-21-011105.txt   169611

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20211014.xsd EX-101.SCH 5607
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vtgn-20211014_cal.xml EX-101.CAL 898
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20211014_def.xml EX-101.DEF 2105
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20211014_lab.xml EX-101.LAB 14244
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20211014_pre.xml EX-101.PRE 9045
9 EXTRACTED XBRL INSTANCE DOCUMENT vtgn_8k_htm.xml XML 3506
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

EIN.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 211324644
SIC: 2834 Pharmaceutical Preparations